Int J Stomatol ›› 2023, Vol. 50 ›› Issue (2): 230-236.doi: 10.7518/gjkq.2023003
• Reviews • Previous Articles Next Articles
CLC Number:
1 | Dang N, Hu J, Liu X, et al. CD167 Acts as a novel costimulatory receptor in T-cell activation[J]. J Immunother, 2009, 32(8): 773-784. |
2 | Iwai LK, Luczynski MT, Huang PH. Discoidin domain receptors: a proteomic portrait[J]. Cell Mol Life Sci, 2014, 71(17): 3269-3279. |
3 | Orgel Joseph PRO, Madhurapantula RS. A structu-ral prospective for collagen receptors such as DDR and their binding of the collagen fibril[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118478. |
4 | Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-me-diated apoptosis and influence p53 regulation through a positive feedback loop[J]. EMBO J, 2003, 22(6): 1289-1301. |
5 | Chang J, Chaudhuri O. Beyond proteases: basement membrane mechanics and cancer invasion[J]. J Cell Biol, 2019, 218(8): 2456-2469. |
6 | Valencia K, Ormazábal C, Zandueta C, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis[J]. Clin Cancer Res, 2012, 18(4): 969-980. |
7 | Hidalgo-Carcedo C, Hooper S, Chaudhry SI, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6[J]. Nat Cell Biol, 2011, 13(1): 49-58. |
8 | Toy KA, Valiathan RR, Núñez F, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2015, 150(1): 9-18. |
9 | Xu M, Cui C. Discoidin domain receptor tyrosine kinase 1 (DDR1): a novel predictor for recurrence of hepatocellular carcinoma after curative resection[J]. Med Sci Monit, 2021, 27: e933109. |
10 | Wu L, Zhao X, Ma H, et al. Discoidin domain receptor 1, a potential biomarker and therapeutic target in hepatocellular carcinoma[J]. Int J Gen Med, 2022, 15: 2037-2044. |
11 | Bonfil RD, Chen W, Vranic S, et al. Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness[J]. Cancer Cell Int, 2021, 21(1): 507. |
12 | Sugimoto K, Ito T, Woo J, et al. Prognostic impact of phosphorylated discoidin domain receptor-1 in esophageal cancer[J]. J Surg Res, 2019, 235: 479-486. |
13 | Chou ST, Peng HY, Mo KC, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1[J]. J Exp Clin Cancer Res, 2019, 38(1): 281. |
14 | Chen YL, Tsai WH, Ko YC, et al. Discoidin domain receptor-1 (DDR1) is involved in angiolymphatic invasion in oral cancer[J]. Cancers (Basel), 2020, 12(4): E841. |
15 | Zhu X, Yao M, Zhang B, et al. Biological information and functional analysis reveal the role of discoidin domain receptor 1 in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(2): 221-230. |
16 | Lai SL, Tan ML, Hollows RJ, et al. Collagen indu-ces a more proliferative, migratory and chemoresistant phenotype in head and neck cancer via DDR1[J]. Cancers (Basel), 2019, 11(11): E1766. |
17 | Takai K, Drain AP, Lawson DA, et al. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers[J]. Genes Dev, 2018, 32(3/4): 244-257. |
18 | Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, et al. Altered expression of DDR1 in clear cell renal cell carcinoma correlates with miR-199a/b-5p and patients’ outcome[J]. Cancer Genomics Proteomics, 2019, 16(3): 179-193. |
19 | Wasinski B, Sohail A, Bonfil RD, et al. Discoidin domain receptors, DDR1b and DDR2, promote tumour growth within collagen but DDR1b suppres-ses experimental lung metastasis in HT1080 xenografts[J]. Sci Rep, 2020, 10(1): 2309. |
20 | Zhao Z, Zhao S, Luo L, et al. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition[J]. Br J Cancer, 2021, 124(5): 982-994. |
21 | Xiao Q, Jiang Y, Liu Q, et al. Minor Type Ⅳ collagen α5 chain promotes cancer progression through discoidin domain receptor-1[J]. PLoS Genet, 2015, 11(5): e1005249. |
22 | Chappell WH, Candido S, Abrams SL, et al. In-fluences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines[J]. Aging (Albany NY), 2020, 12(11): 10194-10210. |
23 | Deng J, Kang Y, Cheng CC, et al. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis[J]. JCI Insight, 2021, 6(17): 146133. |
24 | Dai W, Liu S, Wang S, et al. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma[J]. Signal Transduct Target Ther, 2021, 6(1): 176. |
25 | Ziegler AN, Chidambaram S, Forbes BE, et al. Insulin-like growth factor-Ⅱ (IGF-Ⅱ) and IGF-Ⅱ analogs with enhanced insulin receptor-a binding affinity promote neural stem cell expansion[J]. J Biol Chem, 2014, 289(8): 4626-4633. |
26 | Vella V, Malaguarnera R. The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12): E3814. |
27 | Vella V, Nicolosi ML, Cantafio P, et al. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop[J]. Endocr Relat Cancer, 2019, 26(1): 197-214. |
28 | Di Martino JS, Nobre AR, Mondal C, et al. A tumor-derived type Ⅲ collagen-rich ECM niche regulates tumor cell dormancy[J]. Nat Cancer, 2022, 3(1): 90-107. |
29 | Wang CZ, Su HW, Hsu YC, et al. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration[J]. Mol Biol Cell, 2006, 17(6): 2839-2852. |
30 | Azizi R, Salemi Z, Fallahian F, et al. Inhibition of didscoidin domain receptor 1 reduces epithelial-me-senchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines[J]. J Cell Physiol, 2019, 234(11): 19539-19552. |
31 | Azizi R, Fallahian F, Aghaei M, et al. Down-regulation of DDR1 induces apoptosis and inhibits EMT through phosphorylation of Pyk2/MKK7 in DU-145 and lncap-FGC prostate cancer cell lines[J]. Anticancer Agents Med Chem, 2020, 20(8): 1009-1016. |
32 | Chung VY, Tan TZ, Huang RL, et al. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer[J]. Gene, 2017, 635: 9-15. |
33 | Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition[J]. Matrix Biol, 2011, 30(4): 243-247. |
34 | Le CC, Bennasroune A, Collin G, et al. LRP-1 promotes colon cancer cell proliferation in 3D collagen matrices by mediating DDR1 endocytosis[J]. Front Cell Dev Biol, 2020, 8: 412. |
35 | Xie X, Rui W, He W, et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer[J]. Am J Transl Res, 2017, 9(5): 2500-2507. |
36 | Griffith OL, Spies NC, Anurag M, et al. The prognostic effects of somatic mutations in ER-positive breast cancer[J]. Nat Commun, 2018, 9(1): 3476. |
37 | Ben Arfi K, Schneider C, Bennasroune A, et al. Discoidin domain receptor 1 expression in colon cancer: roles and prognosis impact[J]. Cancers (Basel), 2022, 14(4): 928. |
38 | Reger de Moura C, Battistella M, Sohail A, et al. Discoidin domain receptors: a promising target in melanoma[J]. Pigment Cell Melanoma Res, 2019, 32(5): 697-707. |
39 | Chen Y, Wang X, Deng X, et al. DNA damage repair status predicts opposite clinical prognosis immunotherapy and non-immunotherapy in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 6769-22. |
40 | Dimitrios L, Enrico K. Barring the gates to the battleground: DDR1 promotesimmune exclusion in so-lid tumors[J]. Signal Transduct Target Ther, 2022, 7(1): 17. |
41 | Sun X, Wu B, Chiang HC, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion[J]. Nature, 2021, 599(7886): 673-678. |
42 | Zhong X, Zhang W, Sun T. DDR1 promotes breast tumor growth by suppressing antitumor immunity[J]. Oncol Rep, 2019, 42(6): 2844-2854. |
43 | [No authors listed]. Collagen receptor implicated in immune exclusion[J]. Cancer Discov, 2022, 12(1): 6. |
44 | Vella V, Malaguarnera R, Nicolosi ML, et al. Insulin/IGF signaling and discoidin domain receptors: an emerging functional connection[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118522. |
45 | Vella V, Giuliano M, Nicolosi ML, et al. DDR1 affects metabolic reprogramming in breast cancer cells by cross-talking to the insulin/IGF system[J]. Biomolecules, 2021, 11(7): 926. |
46 | Lin Y, Jin H, Wu X, et al. The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(14): 14391-14405. |
47 | Denny WA, Flanagan JU. Inhibitors of discoidin domain receptor (DDR) kinases for cancer and inflammation[J]. Biomolecules, 2021, 11(11): 1671. |
48 | Tao Y, Wang R, Lai Q, et al. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma[J]. Mol Oncol, 2019, 13(9): 1855-1873. |
49 | Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib[J]. Eur J Pharmacol, 2008, 599(1/2/3): 44-53. |
50 | Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors[J]. Nat Biotechnol, 2019, 37(9): 1038-1040. |
51 | Shariati M, Evans KW, Zheng X, et al. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations[J]. Oncogene, 2021, 40(26): 4425-4439. |
52 | Bhanumathy KK, Balagopal A, Vizeacoumar FS, et al. Protein tyrosine kinases: their roles and their targeting in leukemia[J]. Cancers (Basel), 2021, 13(2): E184. |
53 | Berestjuk I, Lecacheur M, Carminati A, et al. Targe-ting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma[J]. EMBO Mol Med, 2022, 14(2): e11814. |
54 | Vehlow A, Cordes N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy[J]. Autophagy, 2019, 15(8): 1487-1488. |
55 | Vehlow A, Klapproth E, Jin S, et al. Interaction of discoidin domain receptor 1 with a 14-3-3-beclin-1-Akt1 complex modulates glioblastoma therapy sensitivity[J]. Cell Rep, 2019, 26(13): 3672-3683.e7. |